Now that the FDA is resuming drug lab inspections in China three years after the pandemic started, biotech stocks such as Amicus (FOLD), BeiGene (BGNE), Novartis (NVS), and Coherus BioSciences (CHRS) could benefit, writes Josh Nathan-Kazis in Barron’s. Amicus’ Pompe drug was set to be manufactured by Chinese company WuXi Biologics before the FDA delayed its review of the drug because the agency’s inspectors could not visit the WuXi facility in China, while a new cancer treatment from BeiGene and Novartis was also delayed, the author says, noting that another cancer drug from Coherus was also in limbo. Reference Link
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FOLD:
- Amicus price target raised to $17 from $16 at BofA
- Amicus announces European Commission approval for Pombiliti
- Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
- Stifel says SVB fallout ‘appears limited’ across firm’s biotech coverage
- Amicus sees FY23 Galafold revenue growth between 12%-17% at CER